Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]-BMS-986368 ADME Study in Healthy Men
NCT06227975Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bms-986368 in epilepsy, agitation and Spasticity, sponsored by Celgene Corporation. Primary endpoints: Maximum observed concentration, Time of maximum observed concentration and 2 more. Started Feb 2024; status: completed.
02
Drugs
bms-986368
03
Conditions
epilepsyagitationSpasticity
Beyond the preview
Go deeper on NCT06227975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227975.